Q1 2022 Results
Company overview
Financial performance
CRM
Immunology
Financial review
Neuroscience
2022 priorities
Appendix
References
Innovation: Pipeline overview
Innovation: Clinical trials
Abbreviations
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
KisqaliⓇ - CDK4/6 inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT03701334 NATALEE (CLEE011012301C)
Adjuvant treatment of hormone receptor (HR)-positive, HER2-negative, early breast
cancer (EBC)
Phase 3
5101
Invasive Disease-Free Survival for using STEEP criteria (Standardized Definitions
for Efficacy End Points in adjuvant breast cancer trials)
Ribociclib endocrine therapy
Endocrine therapy
Pre and postmenopausal women and men with HR-positive, HER2-negative EBC,
after adequate surgical resection, who are eligible for adjuvant endocrine therapy
2023
Target Patients
Read-out Milestone(s)
Publication
TBD
95 Investor Relations | Q1 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation